Mayne Pharma Group Ltd. · ASX:MYX

Mayne Pharma — Merger or Acquisition (December 2012)

13 slides from Mayne Pharma's merger presentation, Dec 14, 2012

  1. Slide 1: Acquisition of Kapanol®

    For personal use only Mayne Pharma Group Limited Acquisition of Kapanol®

  2. Slide 2: Important Notice and Disclaimer

    Important Notice and Disclaimer For personal use only The following notice and disclaimer applies to this presentation (Presentation) and you are therefore advised to read this carefully before reading or making any other use of this Presentation or any information contained in this Presentation. In

  3. Slide 3: Important Notice and Disclaimer (cont’d)

    Important Notice and Disclaimer (cont’d) For personal use only None of Mayne Pharma’s corporate or financial advisers nor any advisers, financiers or underwriters appointed (being Credit Suisse (Australia) Limited and UBS AG, Australia Branch) (or to be appointed) in respect of any potential offerin

  4. Slide 4: Transaction overview

    Transaction overview  Mayne Pharma Group Limited (“Mayne Pharma”) to acquire Kapanol® and related assets in Australia from GlaxoSmithKline (“GSK”) for up to A$14.0m For personal use only - A$13.5m for trademark, marketing authorisations, product dossier and technical data; plus - Up to A$0.5m for p

  5. Slide 5: Market overview

    Market overview Overview Modified Release (“MR”) Oral Opioid Market1 For personal use only By Volume (m counting units) CAGR  Opioid analgesics are pain relievers that act on the 90 5.7% central nervous system 80 70 60  The opioid analgesic market is worth 50 A$228m in Australia and has achieved a

  6. Slide 6: Overview of Kapanol®

    Overview of Kapanol ®  Kapanol® is an oral opioid containing morphine Kapanol  For personal use only sulphate and is used for the relief of chronic, moderate to severe pain Morphine sulphate binder layer  Mayne Pharma knows Kapanol® well as it originally Extended-release pH developed the product

  7. Slide 7: Compelling strategic rationale

    Compelling strategic rationale  Strong underlying growth fundamentals in the MR Oral Opioid market driven by Australia’s For personal use only 1 Attractive market fundamentals ageing population, increasing incidence of chronic diseases like cancer and the increased use in managing non-malignant chr

  8. Slide 8: Acquisition funding and conditions

    Acquisition funding and conditions For personal use only Placement  Acquisition will be funded via an A$18.0m underwritten placement to institutional and sophisticated investors  61.0 million shares issued at a placement price of A$0.295 per share - 7.8% discount to last close price of Mayne Pharm

  9. Slide 9: Share Purchase Plan

    Share Purchase Plan For personal use only Share Purchase Plan  In addition, eligible Mayne Pharma shareholders will be given the opportunity to apply for new shares up to a maximum value of $10,000 via a Share Purchase Plan - SPP shares will be issued at the Placement price - Total funds raised via

  10. Slide 10: Placement timetable

    Placement timetable1 For personal use only Trading halt in Mayne Pharma shares (before market open) Friday 14th December 2012 Bookbuild opens 10:00am Friday 14th December 2012 Bookbuild closes 3:00pm, Friday 14 December 2012 Mayne Pharma shares recommence trading Monday 17th December 2012 Settlement

  11. Slide 11: Mayne Pharma business update

    Mayne Pharma business update For personal use only  Mayne Pharma has now owned the business for 29 days and sales tracking to plan Metrics  Integration has commenced with project teams across the key identified performing to plan revenue generating projects and functional areas - Management focuse

  12. Slide 12: Foreign Selling Restrictions

    Foreign Selling Restrictions International Offer Restrictions For personal use only This document does not constitute an offer of new ordinary shares ("New Shares") of the Company in any jurisdiction in which it would be unlawful. New Shares may not be offered or sold in any country outside Australi

  13. Slide 13: Foreign Selling Restrictions (cont’d)

    Foreign Selling Restrictions (cont’d) For personal use only Singapore This document and any other materials relating to the New Shares have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this document and any other

Mayne Pharma Group — Merger or Acquisition (December 2012) on 6ix